KZR vs TGTX

TG Therapeutics, Inc.

(TGTX) offers the better valuation at 17. 9x trailing P/E (35. 9x forward), making it the more compelling value choice. Analysts rate TG Therapeutics, Inc. (TGTX) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, TG Therapeutics, Inc.

(TGTX) delivered a total return of +29. 3%, compared to -98. 7% for Kezar Life Sciences, Inc. (KZR). Over 10 years, the gap is even starker: TGTX returned +605. 4% versus KZR's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TG Therapeutics, Inc.

(TGTX) is the lower-risk stock at 0. 65β versus Kezar Life Sciences, Inc. 's 0. 72β — meaning KZR is approximately 10% more volatile than TGTX relative to the S&P 500. On balance sheet safety, Kezar Life Sciences, Inc. (KZR) carries a lower debt/equity ratio of 3% versus 40% for TG Therapeutics, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: TG Therapeutics, Inc.

grew EPS 1747% year-over-year, compared to -566. 1% for Kezar Life Sciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TG Therapeutics, Inc.

(TGTX) is the more profitable company, earning 72. 6% net margin versus 0. 0% for Kezar Life Sciences, Inc. — meaning it keeps 72. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TGTX leads at 20. 0% versus 0. 0% for KZR. At the gross margin level — before operating expenses — TGTX leads at 83. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for TGTX: 10.

1% to $54. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, TG Therapeutics, Inc.

(TGTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65), +605. 4% 10Y return). Both have compounded well over 10 years (TGTX: +605. 4%, KZR: -99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KZR is a small-cap quality compounder stock; TGTX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.